Results 101 to 110 of about 30,146 (272)

A Maximum-Use Trial of Ruxolitinib Cream in Adolescents and Adults with Atopic Dermatitis [PDF]

, 2022
Robert Bissonnette, Robert S. Call, Tooraj Joseph Raoof, Zhaoyin Zhu, Swamy Yeleswaram, Xiaohua Gong, Mark Lee   +6 more
openalex   +1 more source

“Nomen Omen: The Myth of God Janus”

JEADV Clinical Practice, EarlyView.
Alba Guglielmo
wiley   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

Figure S4 from Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis

, 2023
Joe‐Elie Salem, Marie Bretagne, Baptiste Abbar, Sarah Léonard-Louis, Stéphane Éderhy, Alban Redheuil, Samia Boussouar, Lee S. Nguyen, Adrien Procureur, Frederic Stein, Charlotte Fenioux, Perrine Devos, Paul Gougis, Martin Dres, Alexandre Demoule, Dimitri Psimaras, Timothée Lenglet, Thierry Maisonobe, Marc Pineton de Chambrun, Guillaume Hékimian, Christian Straus, Jésus Gonzalez‐Bermejo, David Klatzmann, Aude Rigolet, Perrine Guillaume-Jugnot, Nicolas Champtiaux, Olivier Benvéniste, Nicolas Weiss, Samir Saheb, Philippe Rouvier, Isabelle Plu, Estelle Gandjbakhch, Mathieu Kernéis, Nadjib Hammoudi, Noël Zahr, Claudia Llontop, Capucine Morélot‐Panzini, Lorenz Lehmann, Juan Qin, Javid J. Moslehi, Michèlle Rosenzwajg, Thomas Similowski, Yves Allenbach   +42 more
openalex   +1 more source

Multiplexed Transcriptomics for Screening Drug Combinations and Defining the Mechanism of Action of HCC Therapeutics at Single‐Cell Resolution

Cell Proliferation, EarlyView.
We designed a framework for screening clinical drug combinations with anti‐hepatocellular carcinoma (HCC) activity, comprising four parts: primary screening, single‐cell screening, functional validation, and mechanism research. High‐throughput single‐cell screening identifies HY (HHT and YM155) as a potent anti‐HCC drug combination, validated by in ...
Mengmeng Jiang, Haide Chen, Guoxia Wen, Yuqing Mei, Wenzhao Zhou, Bin Xu, Tingyue Zhang, Guangyan Li, Junqing Wu, Xiaoping Han, Xudong Fu, Guoji Guo, Jingjing Wang   +12 more
wiley   +1 more source

Cord blood T regulatory cells synergize with ruxolitinib to improve GVHD outcomes

Frontiers in Transplantation
BackgroundAdoptive therapy with umbilical cord blood (UCB) T-regulatory (Treg) cells can prevent graft vs. host disease (GVHD). We hypothesize that UCB Tregs can treat GVHD and synergize with ruxolitinib, Jak2 inhibitor, to improve outcomes.MethodsUCB ...
Ke Zeng, Hongbing Ma, Meixian Huang, Mi-Ae Lyu, Tara Sadeghi, Christopher R. Flowers, Simrit Parmar   +6 more
doaj   +1 more source

P1058: REAL-WORLD OUTCOMES WITH FEDRATINIB THERAPY IN PATIENTS WITH PRIMARY MYELOFIBROSIS POST-RUXOLITINIB DISCONTINUATION

, 2022
Francesco Passamonti, Ying Lou, Manoj Chevli, P. Abraham   +3 more
openalex   +1 more source

Ruxolitinib add-on therapy in steroid-refractory graft-vs-host disease following hematopoietic cell transplantation: A single institutional experience [PDF]

, 2023
Yi-Lun Wang, Tsung‐Yen Chang, Yu‐Chuan Wen, Shu-Ho Yang, Yi-Wen Hsiao, Shih‐Hsiang Chen, Tang‐Her Jaing   +6 more
openalex   +1 more source

Pediatric Primary Cutaneous CD8+ Aggressive Epidermotropic Cytotoxic T‐Cell Lymphoma With Unusually Long Clinical Course

Journal of Cutaneous Pathology, EarlyView.
ABSTRACT Primary cutaneous aggressive epidermotropic CD8+ cytotoxic T‐cell lymphoma (PCAECTCL) is a rare and aggressive malignancy, with limited documented cases in pediatric patients. This report presents a unique case of a 9‐year‐old female with PCAECTCL, characterized by widespread erythematous annular lesions that exhibited an indolent clinical ...
Carrie Meng, Auris Huen, David McCall, Phyu P. Aung, Priyadharsini Nagarajan, Valentina Nardi, Carlos A. Torres‐Cabala   +6 more
wiley   +1 more source

Ruxolitinib cream monotherapy demonstrates rapid improvement in the extent and signs of mild to moderate atopic dermatitis across head and neck and other anatomic regions in adolescents and adults: pooled results from 2 phase 3 studies

Journal of Dermatological Treatment
Purpose: Ruxolitinib (selective Janus kinase [JAK] 1 and JAK2 inhibitor) cream demonstrated efficacy and safety in patients with atopic dermatitis (AD) in the phase 3 TRuE-AD studies. In TRuE-AD1/TRuE-AD2 (NCT03745638/NCT03745651), adults and adolescents
Eric L. Simpson, Robert Bissonnette, Zelma C. Chiesa Fuxench, Howard Kallender, Daniel Sturm, Haobo Ren, Linda F. Stein Gold   +6 more
doaj   +1 more source